Researchers from Memorial Sloan Kettering Cancer Center have discovered subclonal co-mutations and immunophenotypic profiles that can distinguish individual cells indicative of future AML relapse from others present after treatment using Mission Bio Inc.’s Tapestri Single-cell Multi-omics Measurable Residual Disease assay.
The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia.
